Topics

MorphoSys Stops Clinical Development MOR106 In Atopic Dermatitis

17:34 EDT 28 Oct 2019 | FinanzNachrichten

MARTINSRIED (dpa-AFX) - MorphoSys AG (MOR) Monday announced it has stopped the clinical development program of MOR106 in atopic dermatitis, due to low probability to meet main goal of study.The co...

Original Article: MorphoSys Stops Clinical Development MOR106 In Atopic Dermatitis

NEXT ARTICLE

More From BioPortfolio on "MorphoSys Stops Clinical Development MOR106 In Atopic Dermatitis"

Quick Search

Relevant Topic

Eczema
Eczema is a common itchy skin disease characterized by reddening and vesicle formation, which may lead to weeping and crusting. It is endogenous, or constitutional. There are five main types; atopic, seborrhoeic, discoid, gravitational or varicose. ...